Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments
- 1 October 1996
- journal article
- review article
- Published by Springer Nature in Nature Biotechnology
- Vol. 14 (10) , 1239-1245
- https://doi.org/10.1038/nbt1096-1239
Abstract
Disulfide-stabilized Fv fragments of antibodies (dsFv) are molecules in which the VH-VL heterodimer is stabilized by an interchain disulfide bond engineered between structurally conserved framework positions distant from complementarity-determining regions (CDRs). This method of stabilization is applicable for the stabilization of many antibody Fvs and has also been applied to a T-cell receptor Fv. A summary of the design strategy, and the construction and production of various dsFvs and dsFv-fusion proteins is presented. Included in the discussion are the biochemical features of dsFvs in comparison with scFvs, the effect of disulfide stabilization on Fv binding and activity, and various applications of dsFvs and dsFv-immunotoxins for tumor imaging and the treatment of solid tumors in animal models.Keywords
This publication has 60 references indexed in Scilit:
- Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genesPublished by Elsevier ,2004
- Thermal stabilization of a single‐chain Fv antibody fragment by introduction of a disulphide bondFEBS Letters, 1995
- Crystal Structure of the β Chain of a T Cell Antigen ReceptorScience, 1995
- Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and tcr fv frameworks are very similar in structureImmunity, 1995
- Cloning, expression and characterization of the Fv fragments of the anti-carbohydrate mAbs Bl and B5 as single-chain immunotoxinsProtein Engineering, Design and Selection, 1994
- Correctly Folded T-cell Receptor Fragments in the Periplasm of Escherichia coli: Influence of Folding CatalystsJournal of Molecular Biology, 1994
- Immunotoxins against cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1994
- Secretion of T cell receptor fragments from recombinant Escherichia coli cellsJournal of Molecular Biology, 1992
- Recombinant Toxins as Novel Therapeutic AgentsAnnual Review of Biochemistry, 1992
- Recombinant Toxins for Cancer TreatmentScience, 1991